← All trials
NCT05733351
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 3, 2023
- Primary completion
- Dec 16, 2026
- Completion date
- Dec 16, 2027
- First posted
- Feb 17, 2023
- Last posted
- Aug 21, 2023
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emory UniversityLead sponsor
- National Cancer Institute (NCI)Collaborator
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- XencorCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.